Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03133312
Other study ID # VAGPrep
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 2, 2017
Est. completion date December 30, 2017

Study information

Verified date March 2019
Source Metro Health, Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Hypothesis: chlorhexidine gluconate antiseptic vaginal preparation is superior to povidone-iodine vaginal preparation in decreasing the bacterial load within the vagina when prepping prior to a cesarean section.


Description:

Patients who are planning cesarean will be recruited and consented for study participation at time of admission to labor and delivery.

Patients undergoing cesarean who meet inclusion/exclusion criteria will be randomized to one of two surgical preparations as follows: 1. Chlorhexidine gluconate (CHG); or, 2. Povidone-iodine scrub. Randomization will be performed by the consenting surgeon (listed as key personnel) after the patient has arrived into the operating room for cesarean. To establish baseline bacterial load, a qualitative BAL culture will be collected prior to the vaginal preparations. Pre-operative surgical site antisepsis will be performed according to randomization. All other surgical practices will remain at the surgeon's discretion according to standard of care at Metro Health Hospital.

At the completion of the cesarean, it is standard practice to perform a manual evacuation of blood clots from the lower uterine segment. The study culture will be obtained by the consenting surgeon immediately prior to manual evacuation. The cultures will then be sent to the lab for determination of total bacterial load of the vaginal area. The lab will be blinded toward which type of vaginal prep was used. Total colony count will be determined by certified lab personnel by adding all counts regardless of bacteria type. A secondary chart review will be performed by the investigator within 30 days of the postoperative period to evaluate for length of hospital stay, pain level, blood loss, any additional antibiotics received postoperatively, and the development of post-operative infection in subjects up to 30 days after discharge.

The research project will take place over a 12-month period of time at Metro Health Hospital. In review of Metro Health Labor and Delivery statistics for scheduled cesarean sections performed in 2016, an average of 18.8 were performed a month, giving a total of approximately 226 in a one-year period. Based on the research study published by Culligan, Kubik, Murphy, et al. comparing the two vaginal preparations for vaginal hysterectomy, an estimated sample size was calculated. Using the 90 minute colony counts of 20,472 (40,058) vs 1,221 (2,857), and using an alpha of .05 and power of 80% investigator found the sample size for each group should be at least 27. This sample size (27 X 2 groups) is very close to the sample size (50) in the Culligan experiment. In an attempt to ensure the most clinically significant, investigators anticipate screening between 70-100 patients with approximately 70-80% participation.

Analysis will be performed by the investigators for completeness, accuracy, strict adherence to study protocol, safety, and statistical significance. The investigators are also subject to periodic audits by the Institutional Review Board (IRB).


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 30, 2017
Est. primary completion date December 30, 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Scheduled low transverse cesarean section (can be primary or repeat)

- Term gestation = 37 weeks

Exclusion Criteria:

- Allergy to either antiseptic

- Rupture of amniotic membranes

- Preterm gestation

- Active labor

- Emergency or unscheduled cesarean sections

- Infection diagnosis on admission

- Vaginal infection or any treatment of vulvovaginitis in prior 7 days

- Patients under the age of 18 years

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chlorhexidine Gluconate
Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
Povidone-Iodine Scrub and Paint
Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention

Locations

Country Name City State
United States Metro Health Wyoming Michigan

Sponsors (1)

Lead Sponsor Collaborator
Metro Health, Michigan

Country where clinical trial is conducted

United States, 

References & Publications (4)

Culligan PJ, Kubik K, Murphy M, Blackwell L, Snyder J. A randomized trial that compared povidone iodine and chlorhexidine as antiseptics for vaginal hysterectomy. Am J Obstet Gynecol. 2005 Feb;192(2):422-5. — View Citation

Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, Miller HJ, Awad SS, Crosby CT, Mosier MC, Alsharif A, Berger DH. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med. 2010 Jan 7;362(1):18-26. doi: 1 — View Citation

Levin I, Amer-Alshiek J, Avni A, Lessing JB, Satel A, Almog B. Chlorhexidine and alcohol versus povidone-iodine for antisepsis in gynecological surgery. J Womens Health (Larchmt). 2011 Mar;20(3):321-4. doi: 10.1089/jwh.2010.2391. Epub 2011 Feb 16. — View Citation

Tuuli MG, Liu J, Stout MJ, Martin S, Cahill AG, Odibo AO, Colditz GA, Macones GA. A Randomized Trial Comparing Skin Antiseptic Agents at Cesarean Delivery. N Engl J Med. 2016 Feb 18;374(7):647-55. doi: 10.1056/NEJMoa1511048. Epub 2016 Feb 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Post-Operative Infection Presence of post-operative infection including endometritis, pelvic abscess, and skin/wound up to 30 day post-operative
Primary Bacterial Load Change in total bacterial load from baseline (pre-operative) vaginal culture Immediately Post-operative prior to exit from operating room
Secondary Length of Hospital Stay Number of days 2 or 3 post-operative days
See also
  Status Clinical Trial Phase
Recruiting NCT05846399 - CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE) Phase 4
Recruiting NCT05904535 - Novel Diagnostic Methods to Identify External Ventricular Drain Associated Infections
Not yet recruiting NCT04075344 - Effect of a Infection Control Program on the Reduction of Bacterial Contamination on NG Tube Feeding in RCHEs N/A
Completed NCT05333133 - High Calorie Formula Intervention on Weight, Length Increment, Total Lymphocyte Counts, TNF-alpha and IGF-1 in Failure to Thrive Children N/A
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Recruiting NCT06283433 - A Dried Blood Spot Sampling Method for Vancomycin and Creatinine Monitoring for OPAT N/A
Recruiting NCT06178822 - Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
Completed NCT03688321 - Probiotic on Prevention of GBS Vaginal Infection During Pregnancy N/A
Completed NCT03244917 - Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias N/A
Recruiting NCT04450680 - Beta-lactam Therapeutic Drug Monitoring in Singapore
Completed NCT05686577 - How to Reduce Unnecessary Blood Cultures: Construction and Validation of a Predictive Score for Blood Culture Positivity in Intensive Care
Recruiting NCT06093269 - Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL) Phase 4
Recruiting NCT05587283 - Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women Phase 1
Recruiting NCT03752424 - Topical Silver Nanoparticles for Microbial Activity Phase 1
Completed NCT04440631 - Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
Active, not recruiting NCT05150015 - ElastoMeric Infusion Pumps for Hospital AntibioTICs N/A
Completed NCT03816956 - Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 Phase 3
Terminated NCT03555981 - Early Kangaroo Mother Care in Gambian Hospitalised Unstable Neonates N/A
Recruiting NCT04800575 - Comparison of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Central Venous Catheter N/A
Completed NCT03925402 - Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia